A Meta-Analysis of Efficacy and Safety of Infliximab for Prevention of Postoperative Recurrence in Patients with Crohn’s Disease

Table 1

The characteristics of the 7 included trials.

Study	Drug Regimen	Follow-up	Type of Ileocolonic Resection	Timing of Initiation of Treatment	Recurrence Definition	Patients(n)	Endoscopic Recurrence (%)	Clinical
		(month)						Recurrence (%)
Sorrentino et al.	IFX 5mg/kg	24	Macroscopically diseased bowel resected	2 weeks postresection	Clinical:Hanauer>2,Endoscopic: Rutgeerts scor≥2	7	0(0)	0(0)
	MES2.4g/d					16	12(75)	4(25)
Regueiro et al.	IFX 5mg/kg	12	Macroscopically diseased bowel resected	within 4 weeks of resection	Clinical:CDAI>150,Endoscopic: Rutgeerts scor≥2	11	1(9)	2(18)
	Placebo					13	11(85)	6(46)
Yoshida et al.	IFX 5mg/kg	12	Macroscopically diseased bowel resected	4 weeks postresection	Clinical:CDAI>150,Endoscopic: Rutgeerts scor≥2	15	4(26)	2(13)
	No treatment					16	13(81)	4(25)
Armuzzi et al.	IFX 5mg/kg	12	Curative ileocolonic resection	2-4 weeks postresection	Clinical:HBI>8,Endoscopic: Rutgeerts scor≥2	11	1(9)	1(9)
	AZA 2.5mg/kg/d					11	5(45)	2(18)
Tursi et al.	IFX 5mg/kg	12	Curative ileocolonic resection	within 4-6 weeks of resection	Clinical:HBI>8,Endoscopic: Rutgeerts scor≥2	10	2(20)	1(10)
	ADA 40mg EOW					10	1(10)	1(10)
Regueiro et al.	IFX 5mg/kg	12	Macroscopically diseased bowel resected	within 6 weeks of resection	Clinical:CDAI>200,Endoscopic: Rutgeerts scor≥2	147	45(31)	19(13)
	Placebo					150	90(60)	30(20)
Fukushima et al.	IFX 5mg/kg	24	Curative ileocolonic resection	within 8 weeks of resection	Clinical:CDAI>150,Endoscopic: Rutgeerts scor≥2	19	4(21)	4(22)
	Placebo					19	13(68)	13(69)

IFX, infliximab; MES, mesalamine; ADA, adalimumab; AZA, azathioprine; CDAI, Crohn’s disease activity index; EOW, every other week; HBI, Harvey-Bradshaw index.